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Transthyretin (TTR) amyloidosis is considered a rare disease by many cardiologists, yet the past decade has seen a substantial increase in diagnosis, suggesting that it is more common than previously thought. 1 In addition to greater awareness and recognition of typical echocardiographic abnormalities, the use of simple but highly sensitive and specific imaging with bone tracers [ Tc-pyrophosphate (PYP) 2 in the USA] or more advanced imaging such as cardiac magnetic resonance imaging have rendered the diagnosis more easily made. Thus many cardiologists, particularly those with an interest in cardiomyopathy, will have experienced a recent surge in diagnosis of wild-type TTR amyloidosis (ATTRwt), and probably a more frequent diagnosis of the Afro-Caribbean amyloidogenic TTR variant, Val122Ile, which is carried by 1 in 30 subjects of African descent living in Europe and the USA. 3 The burden of TTR amyloidosis among heart failure patients is not small. Small series of patients have tantalizingly implied that >10% of patients with diastolic heart failure may have a contributing component of ATTRwt amyloid, 4 and that the Val122Ile variant TTR amyloidosis is the fourth most common cause of heart failure in Afro-Caribbean patients in London. 5 A diagnosis of TTR cardiac amyloidosis as a cause of heart failure may not, until recently, have helped the individual patient much, except for avoidance of potentially harmful drug therapy such as calcium channel blockers and possibly beta-blockade. However, this is changing rapidly. Amyloidogenesis can be slowed or prevented by stabilizing the precursor protein (TTR) or by significantly lowering TTR levels, two very different mechanisms. 6 The first trial of a TTR stabilizer, tafamadis, is expected to report results by mid-2018, 7 and transthyretin- Transthyretin cardiomyopathy may present as new-onset heart failure or atrial arrhythmia, or may be identified in an asymptomatic patient investigated for an abnormal electrocardiogram. However, the rapid advances in understanding and diagnosis of TTR cardiomyopathy have been ahead of our ability to offer an accurate prognosis at the time of diagnosis. For example, while there is no doubt that untreated cardiac TTR amyloidosis has a far better prognosis than untreated cardiac light-chain (AL) amyloidosis, there remains debate as to whether ATTRwt and mutant TTR (ATTRm) cardiomyopathies differ in prognosis (and, if so, why) and whether subgroups of ATTRm amyloidosis cardiomyopathy with differing prognoses can be identified. 8, 9 Although TTR amyloidosis is increasingly diagnosed, it is still relatively uncommon, and clinical trials, current and planned, are by necessity quite small. Given the rapidly emerging novel therapies, the ability to precisely determine prognostic groups for risk stratification in clinical trials becomes critical, in order to avoid a false-negative outcome of an effective drug. It is for this and other reasons that an accurate staging system would be of great value. A staging system for AL amyloidosis was developed some years ago by the Mayo Clinic. 10 It included patients with a spectrum of cardiac and non-cardiac disease, but of the three prognostic factors on multivariate analysis, two (NT-proBNP and troponin T) are markers of cardiac involvement, with the third a haematological marker. Based on the subsequent use and utility of this staging system, the same group published data showing that NT-proBNP and troponin T are useful in stratifying risk in ATTRwt using similar cut-off values. 12 Unlike the Mayo system, they did not include troponin in their system, but instead included the estimated glomerular filtration rate (eGFR), derived using the MDRD (Modification of Diet in Renal Failure) equation. 13 The model was validated on an unrelated French cohort of patients, and found to be very reproducible. The authors concluded that their staging system 'based on two universally measured biomarkers-is an important advance in the management of cardiac amyloidosis'. While they are to be congratulated on this new staging system, before it is widely adopted it should be carefully analysed to determine whether it is indeed superior to the Mayo Clinic system, and thought should be given as to whether there may even be alternative approaches that are more superior. The omission of troponin T from the Gillmore model is troubling. 12 This biomarker has been shown to be an independent predictor of mortality in acute heart failure and cardiomyopathies, 14, 15 including AL amyloidosis, 10 and is an integral part of the staging system for ATTRwt described by Grogan et al. 11 The decision to evaluate eGFR as a prognostic factor in the current study was based upon a multivariate analysis of prognostic indicators in TTR amyloidosis that excluded troponin, even though troponin T was a significant predictor of mortality on univariate analysis. 12, 16 The primary reason that the authors cite for not using troponin is the number of different assays, the apparent lack of interchangeability between assays, and the non-'universal' availability of troponin. However, in the authors' own analysis, both troponin T and high sensitivity troponin T were univariate predictors of mortality, and the combination of NTproBNP and troponin in the test cohort fared very similarly to the NT-proBNP and eGFR combination, although its performance on the validation cohort is not reported. We find it puzzling that troponin should be considered a biomarker that is not 'universally available' whereas this is not considered to be the case for NT-proBNP. Certainly, in the USA, NT-proBNP, although widely available, is not as widely available as troponin assays, as there are many labs for whom BNP remains the biomarker of choice. More importantly, NTproBNP and troponin release in cardiac amyloidosis presumably reflects different mechanisms of myocyte dysfunction, with the elevation of NT-proBNP levels caused predominantly by myocyte distortion by abutting amyloid deposits, and elevation in troponin reflecting some degree of irreversible cellular dysfunction. Thus, the incorporation of this biomarker into a prognostic model would appear to have advantages. In contrast, eGFR primarily reflects underperfusion of the kidneys in this older population, due to reduced stroke volume from the amyloid cardiomyopathy superimposed on the reduced renal reserve that occurs with ageing. The eGFR is independent of neither troponin nor NT-proBNP levels, as both are affected by the level of renal dysfunction. This can be seen by a simple analysis of the relationship between the elevation of the NT-proBNP and impaired renal function in the paper under discussion, where a two-sided Fisher's exact test shows a highly significant association (P < 0.0001). It is difficult to understand why two related variables (troponin and eGFR) should be superior to two unrelated (or at least less-related) variables, namely NT-proBNP and troponin.
One can debate the relative value of the two published systems, and a back to back evaluation in a validation cohort would be of interest. However, we believe that such a debate overlooks a better, more advanced approach. The Mayo and London systems are both binary systems, utilizing a single cut-off of each of two variables. In order to simplify use, neither examined whether either of the two variables carries more weight, and this would potentially increase complexity of use and decrease group size. Stratification by three variables (NT-proBNP, eGFR, and troponin) with variable weight given to each of these would render the system too complex for bedside assessment, and probably would render even the 869 patient group too small for meaningful analysis. Is there a solution? We would suggest that both the current systems are of interest, but are merely waystations on the road to a better staging system based not on binary choices ('high NT-proBNP, yes/no', 'low eGFR, yes/no') but on the increasingly popular and useful concept of 'machine learning'. Binary systems have the advantage and superficial appearance of simplicity of use, yet by their very simplicity they cannot offer anything more than a modest prediction of outcome in an individual patient. In contrast, machine learning algorithms learn from the data without explicit direction, allowing for discovery of phenotypes present within a disease population. Not only this but, by overcoming statistical assumptions necessary for traditional modelling approaches, machine learning algorithms can provide superior predictions, as has been done for assessing risk of cardiovascular disease, where a battery of machine learning approaches was used and all performed better than traditional models. 17 As pointed out by Goldstein et al. 18 in a recent review of the topic 'For studies where the goal is to predict the occurrence of an outcome -traditional regression models can be modified or abandoned in favour of models that produce a more flexible relationship among the predictor variables and the outcome.' Thus, it seems almost archaic to be using a binary system of two variables, when a model can be developed potentially to detect outcomes more precisely, based on several non-binary variables. Such an outcome predictor could be easily accessed on a website, or even appear as an app for a smartphone, and could incorporate variables such as age, sex, biomarkers, renal function, electrolytes, and possibly basic echocardiographic parameters. What would it take to develop such a model? Willingness among amyloid centres to pool data on their ATTR cardiomyopathy patients to develop a large data set, expert statistical input to develop an appropriate analysis of these data sets, and rigorous internal and external validation. Most academic medical centres have the expertise to perform such an analysis, and the development of such a model could help to refine the design of upcoming clinical trials in TTR amyloid, to answer questions about the differences, if any, between ATTRwt cardiomyopathy and ATTRm cardiomyopathy (and possibly to tease out differences in prognosis in different mutations). In addition, if the TTR-silencing agents show effectiveness in slowing amyloid cardiomyopathy and the TTR stabilizers also show a beneficial effect, machine learning may be able to identify patients in the future who will benefit from one or other class of drug, or who may need combination therapy. We believe that our colleagues in the field of amyloidosis put patient care in the centre of their academic ventures, and we see collaboration in this field as an opportunity not only to refine care for patients with amyloid cardiomyopathy, but also as a chance to be pioneers in
